

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

December 15, 2021

Ilya Rachman Chief Executive Officer Immix Biopharma, Inc. 11400 West Olympic Blvd., Suite 200 Los Angeles, CA 90064

Re: Immix Biopharma, Inc.

Amendment No. 2 to Registration Statement on Form S-1

Exhibit Nos. 10.3 and 10.8 Filed October 15, 2021 File No. 333-259591

Dear Dr. Rachman:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance